Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/23/2017 03/24/2017 03/27/2017 03/28/2017 03/29/2017 Date
1.2(c) 1.21(c) 1.19(c) 1.19(c) 1.1999(c) Last
124 494 135 908 178 466 268 333 88 075 Volume
+2.33% +0.83% -1.65% 0.00% +0.83% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -28,4 M
Net income 2017 -28,3 M
Finance 2017 39 976 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -35,3 M
Net income 2018 -36,5 M
Debt 2018 194 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 114 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development.It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others.Its products include PLacental... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on PLURISTEM THERAPEUTICS INC
10:16p PLURISTEM THERAPEUTICS INC : Change in Directors or Principal Officers, Amendmen..
10:01p Pluristem Launches Co-CEO Structure and Appoints New CFO
01:40p BLUEBIRD BIO : EU rapid drug approval plan worries some national agencies
02/13 Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2..
02/09 PLURISTEM THERAPEUTICS : reports 2Q loss
02/08 PLURISTEM THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
01/27 PLURISTEM THERAPEUTICS : Announces Closing of Bought Offering and Underwriters E..
01/25 Pluristem Announces Closing of Bought Offering and Underwriter’s Exerci..
01/22 PLURISTEM THERAPEUTICS : raises $15m, Can-Fite raises $5m
01/22 PLURISTEM THERAPEUTICS : Increases Previously Announced Bought Deal Offering of ..
More news
Sector news : Biotechnology & Medical Research - NEC
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03/10Get the latest news and updates for $KBH $VRUS $LNTH $PSTI $TSU automatically.. 
02/22Will Pluristem's Acute Radiation Syndrome Trial Results In May Bring Some Pot.. 
02/15Zacks Investment Research Upgrades Pluristem Therapeutics, Inc. $PSTI to “Buy.. 
02/15Pluristem Therapeutics upgraded by Zacks Investment Research to buy. $1.25 PT.. 
02/13Pluristem Therapeutics downgraded by Maxim Group to hold.  
More tweets
Qtime:10
News from SeekingAlpha
02/22 Will Pluristem's Acute Radiation Syndrome Trial Results In May Bring Some Pot..
01/20 Midday Gainers / Losers
01/20 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
01/20 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
01/20 Pluristem increases underwriting deal with Wainwright to $15M; shares down 17..
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Technical analysis trends PLURISTEM THERAPE...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,25 $
Spread / Average Target 173%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Zami Aberman Chairman & Chief Executive Officer
Yaky Yanay President, COO, CFO, Secretary & Director
Esther Lukasiewicz-Hagai Vice President-Clinical & Medical Affairs
Mark S. Germain Director
Nachum Rosman Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS..-16.78%114
INCYTE CORPORATION39.10%28 429
QUINTILES IMS HOLDINGS..3.48%18 567
LONZA GROUP AG3.12%10 618
CELLTRION, INC.--.--%9 982
SEATTLE GENETICS, INC.22.17%9 187
More Results